Keywords: cipramil, sales, driving, lundbeck, growth, danish, drugmaker
Cipramil sales driving Lundbeck growth
Article | 16 May 2001
Danish drugmaker Lundbeck says that revenues in the first quarter of2001 rose 42% to 1.66 billion Danish kroner ($194.6 million), while pretax profits ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
